Nitya Nathwani, M.D.
- Multiple Myeloma
- Multiple Myeloma
- Associate Professor, Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
1996-2002, M.B.B.S., Topiwala National Medical College, Mumbai, India
1994-1996, H.S.C., Science, Jai Hind College, Mumbai, India
2011-2012, Bone Marrow Transplant Fellowship, City of Hope, Duarte, CA
2007-2010, Hematology-Oncology Fellowship, LAC+USC Medical Center, Los Angeles, CA
2004-2007, Internal Medicine Residency, LAC+USC Medical Center, Los Angeles, CA
2001-2002, Rotating Extern at Methodist Hospitals, Merrillville, IN
2022-present, Medical Director, Hematologic Malignancies, Transplantation, and Cellular Therapy, AccessHopeTM
2020-present, Associate Professor, Division of Myeloma, Department of Hematology & Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2012-2020, Assistant Clinical Professor, Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Awards & Memberships
Memberships
2020, Clinical Path Multiple Myeloma Medical Oncology Committee
2017, National Comprehensive Cancer Network (NCCN) Cancer in HIV-Positive Patients’ Panel
2017, NCCN AIDS Related Kaposi Sarcoma Panel
2012, Cancer and Aging Research Group
2011, American Society for Blood and Marrow Transplantation
2011, Los Angeles County Medical Association
2008, American Society of Hematology
2007, American Society of Clinical Oncology
2004, American College of Physicians
Publications
Chhabra S , Callander N , Watts N , Costa L, Thapa B, Kaufman J, Laubach J, Sborov D, Reeves B, Rodriguez C, Chari A, Silbermann R , Anderson Jr L, Bal S, Dhakal B, Nathwani N, et al. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. doi: 10.1016/j.jtct.2022.11.029. PMID: 36494017
Lee K, Nathwani N, Shamunee J, Lindenfeld L, Wong FL, Krishnan A, Armenian S. Telehealth exercise to Improve Physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial. Trials. 2022 Nov 3;23(1):921. doi: 10.1186/s13063-022-06848-y. PMID: 36329525
Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 2022 Sep 16;. doi: 10.1038/s41375-022-01691-1. [Epub ahead of print] PubMed PMID: 36114265.
P.G. Richardson, S.J. Jacobus, E.A. Weller, H. Hassoun, S. Lonial, N.S. Raje, E. Medvedova, P.L. McCarthy, E.N. Libby, P.M. Voorhees, R.Z. Orlowski, L.D. Anderson, Jr., J.A. Zonder, C.P. Milner, C. Gasparetto, M.E. Agha, A.M. Khan, D.D. Hurd, K. Gowin, R.T. Kamble, S. Jagannath, N. Nathwani, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine. 2022. Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. PMID: 35660812
Nathwani N, Bell J, Cherepanov D, Ginchereau Sowell F, Shah R, McCarrier K, Hari P. Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. Supportive Care in Cancer. 2022 Jul;30(7):5859-5869. doi: 10.1007/s00520-022-06979-7. Epub 2022 Apr 1. PMID: 35364733
Nathwani N, Bertamini L, Banjeree R, Gay F, Shah N, Krishnan A. When and How to Treat Relapsed Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2021 Mar;41:358-375. doi: 10.1200/EDBK_320129 PMID: 34010043
Voorhees PM, Rodriguez C, Reeves B, Nathwani N, et al. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma: Updated Efficacy and Safety Analysis of the Safety Run-in Population of GRIFFIN Blood Adv 2021 Feb 23;5(4):1092-1096. doi: 10.1182/bloodadvances.2020003642. PMID: 33606004
- Krishnan A, Adhikarla V, Poku E, Palmer J, Chaudhry A, Biglang-awa V, Bowles N, Nathwani N, et al. Identifying CD38+ cells in patients with multiple myeloma: First-in-human imaging using copper-64-labeled daratumumab. Blood Advances 2020 October 27; 4(20):5194-5202 PMID: 33095874
- Nathwani N, Palmer J, Synold TW, et al. Toxicities associated with metformin/ritonavir combination treatment in relapsed/refractory multiple myeloma. Clinical Lymphoma Myeloma and Leukemia, 2020 May 29; S2152-2650(20)30263-9. PMID 32631779
- Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, et al. Daratumumab, lenalidomide, bortezomib, & Dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood. 2020 Apr 23: PMID: 32325490
- Nathwani N, et al. Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions. J Oncol Pract. 2019 Nov 25:JOP1900208. doi: 0.1200/JOP.19.00208. PMID: 3176526
- Rosenzweig M, Palmer J, Tsai N, Synold T, Wu X, Tao S, Hammond S, Buettner R, Duarte L, Htut M, Karanes C, Nathwani N, et al. Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Study. Leuk Lymphoma. 2020 Apr 8:1-9. doi: 10.1080/10428194.2020.1742900. PMID: 32268821
- Hsu T, Nathwani N, Loscalzo M, Hurria A, et al. Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. J Am Geriatr Soc. 2019 May;67(5):978-986. doi: 10.1111/jgs.15841. Epub 2019 Mar 22. PMID:30901083
- Al Malki M, Nathwani N, et al (co-first author). Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018 May 9. PMID 29753158
- Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A et al. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Aug;16(8):986-1017. doi: 10.6004/jnccn.2018.0066. PMID: 30099375
- Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Crysler OV, Gupta N, Gustafson C, Hall A, Johung KL, Klopp A, LaCasce AS, Lin C, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, et al. AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2019 Feb;17(2):171-189. doi: 10.6004/jnccn.2019.0008. PMID: 30787130
- Armenian SH, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, Wong FL, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer. 2018 Feb 15;124(4):850-857. doi: 10.1002/cncr.31110. Epub 2017 Nov 7.PMID: 29112235
- Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, et al. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017 Dec 18. PMID 29249822
- Hurria A, Akiba C, Kim J, Mitani D, Loscalzo M, Katheria V, Koczywas M, Pal S, Chung V, Forman S, Nathwani N, Fakih M, et al. Reliability, Validity, and Feasibility of a Computer Based Geriatric Assessment for Older Adults with Cancer. Journal of Oncology Practice 2016. 2016 Sep 13. pii: JOPR013136. PMID: 27624950
- Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015 Mar;100(3):357-62
- Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK. Differential effects of apolipoprotein A-I–mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110(12): 1701-1705.